Tecfidera's slowdown, mixed data for aducanumab in Alzheimer's disease, and two smaller pipeline disappointments (Tysabri in stroke and neublastin in sciatica) have put pressure on Biogen reported ...
DUBLIN--(BUSINESS WIRE)--The "Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer's Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback